BioSpace News Archive

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Integrated Safety Analysis from the Phase 3 FINCH and Phase 2 DARWIN Programs Informs the Long-Term Safety Profile of Filgotinib in RA

Accent to receive a $55M USD upfront payment and is eligible for up to approximately $1.1B USD in total additional milestones, plus tiered royalties, under co-development and co-commercialization arrangement

IRLAB’s clinical Phase IIb/III study with the drug candidate mesdopetam in development for the treatment of levodopa induced dyskinesia in Parkinson’s disease, will have a study design with the following main points

First COVID-19 vaccine clinical study approved in South Korea funded by CEPI through INOVIO, and supported by KCDC/KNIH

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Follica, Inc. announced positive feedback from a meeting with the U.S. Food and Drug Administration as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019.

MTx’s DROPZYLLA® platform isolated ultra-rare and highly potent virus-neutralizing antibodies from COVID-19 patients within six weeks

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company has received positive results from the first clinical study with ACD856, aiming to evaluate half-life in humans.

Breast implants are one of the most commonly sought and studied medical devices in history.